current user: public
If you have questions about the server, please let us know.

Query: gi|6319279|ref|NP_009362.1| Pyruvate kinase, functions as a homotetramer in glycolysis to convert phosphoenolpyruvate to pyruvate, the input for aerobic (TCA cycle) or anaerobic (glucose fermentation) respiration; Cdc19p (YAL038W) [Saccharomyces cerevisiae], from S.cerevisiae

Results of FFAS03 search in PDB1018
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .  340    .  350    .  360    .  370    .  380    .  390    .  400    .  410    .  420    .  430    .  440    .  450    .  460    .  470    .  480    .  490    .  500
# Score Template Links and tools%idFirst MSRLERLTSLNVVAGSDLRRTSIIGTIGPKTNNPETLVALRKAGLNIVRMNFSHGSYEYHKSVIDNARKSEELYPGRPLAIALDTKGPEIRTGTTTNDVDYPIPPNHEMIFTTDDKYAKACDDKIMYVDYKNITKVISAGRIIYVDDGVLSFQVLEVVDDKTLKVKALNAGKICSHKGVNLPGTDVDLPALSEKDKEDLRFGVKNGVHMVFASFIRTANDVLTIREVLGEQGKDVKIIVKIENQQGVNNFDEILKVTDGVMVARGDLGIEIPAPEVLAVQKKLIAKSNLAGKPVICATQMLESMTYNPRPTRAEVSDVGNAILDGADCVMLSGETAKGNYPINAVTTMAETAVIAEQAIAYLPNYDDMRNCTPKPTSTTETVAASAVAAVFEQKAKAIIVLSTSGTTPRLVSKYRPNCPIILVTRCPRAARFSHLYRGVFPFVFEKEPVSDWTDDVEARINFGIEKAKEFGILKKGDTYVSIQGFKAGAGHSNTLQVSTVLast
1 -137.0001a3w_A mol:protein length:500 PYRUVATE KINASE  ali model follow..  100  1MSRLERLTSLNVVAGSDLRRTSIIGTIGPKTNNPETLVALRKAGLNIVRMNFSHGSYEYHKSVIDNARKSEELYPGRPLAIALDTKGPEIRTGTTTNDVDYPIPPNHEMIFTTDDKYAKACDDKIMYVDYKNITKVISAGRIIYVDDGVLSFQVLEVVDDKTLKVKALNAGKICSHKGVNLPGTDVDLPALSEKDKEDLRFGVKNGVHMVFASFIRTANDVLTIREVLGEQGKDVKIIVKIENQQGVNNFDEILKVTDGVMVARGDLGIEIPAPEVLAVQKKLIAKSNLAGKPVICATQMLESMTYNPRPTRAEVSDVGNAILDGADCVMLSGETAKGNYPINAVTTMAETAVIAEQAIAYLPNYDDMRNCTPKPTSTTETVAASAVAAVFEQKAKAIIVLSTSGTTPRLVSKYRPNCPIILVTRCPRAARFSHLYRGVFPFVFEKEPVSDWTDDVEARINFGIEKAKEFGILKKGDTYVSIQGFKAGAGHSNTLQVSTV 500
2 -134.0001pkm_A mol:protein length:530 M1 PYRUVATE KINASE  ali model follow..  48  24.TFLEHMCRLDIDSPPTARNTGIICTIGPASRSVEILKEMIKSGMNVARLNFSHGTHEYHAETIKNVRAATESFRYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENVLWLDYKNICKVVEVGSKVYVDDGLISLLVKEK-GADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELVRGSSHSTDLMEAMAMGSVEASYKCLAAALIVLTESGRSAHQVARYRPRAPIIAVTRNHQTARQAHLYRGIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKARGFFKHGDVVIVLTGWRPGSGFTNTMRVVPV 529
3 -133.0001pkn_A mol:protein length:530 PYRUVATE KINASE  ali model follow..  49  24.TFLEHMCRLDIDSAPTARNTGIICTIGPASRSVETLKEMIKSGMNVARMNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMAACDENILWLDYKNICKVVEVGSKVYVDDGLISLQVKQK-GPDFLVTEVENGGFLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVDEDVDMVFASFIRKAADVHEVRKILGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMIIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELARSSSHSTDLMEAMAMGSVEASYKCLAAALIVLTESGRSAHQVARYRPRAPIIAVTRNHQTARQAHLYRGIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKAAGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 529
4 -133.0003n25_A mol:protein length:531 Pyruvate kinase isozymes M1/M2  ali model follow..  49  25.TFLEHKCRLDIDSAPTARNTGIICTIGPASRSVETLKEMIKSGMNVARMNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVDVGSKVYVDDGLISLQVKQK-GPDFLVTEVENGGFLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKAADVHEVRKILGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMIIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELARASSQSTDLMEAMAMGSVEASYKCLAAALIVLTESGRSAHQVARYRPRAPIIAVTRNHQTARQAHLYRGIFPVVCKDPVQEAWAEDVDLRVNLAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 530
5 -132.0003srf_C mol:protein length:551 Pyruvate kinase isozymes M1/M2  ali model follow..  49  39.TFLEHMCRLDIDSPPTARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQK-GADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAMFHRKLFEELVRASSHSTDLMEAMAMGSVEASYKCLAAALIVLTESGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 544
6 -131.0004ima_A mol:protein length:543 Pyruvate kinase  ali model follow..  49  37.TFLEHLCLLDIDSEPAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFSHGSHEYHAESIANVREAVESFSYRPVAIALDTKGPEIRTGILQGGSEVELVKGSQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKI-GPEGLVTQVENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAALGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNLAGKPVVCATQMLESMITKARPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKMQHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCMAAAIIVLTTTGRSAQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESGKLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSI 542
7 -131.0003srd_A mol:protein length:551 Pyruvate kinase isozymes M1/M2  ali model follow..  50  39.TFLEHMCRLDIDSPPTARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQK-GADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 544
8 -130.0004jpg_A mol:protein length:556 Pyruvate kinase isozymes M1/M2  ali model follow..  50  44.TFLEHMCRLDIDSPPTARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQK-GADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 549
9 -130.0004hyv_A mol:protein length:499 Pyruvate kinase 1  ali model follow..  47  1MSQLEHNIGLSIFEPVKHRANRIVCTIGPSTQSVEALKNLMKSGMSVARMNFSHGSHEYHQTTINNVRAAAAEL-GLHIGIALDTKGPEIRTGLFKDG-EVSFAPGDIVCVTTDPAYEKVGTKEKFYIDYPQLTNAVRPGGSIYVDDGVMTLRVVSKEDDRTLKCHVNNHHRLTDRRGINLPGCEVDLPAVSEKDRKDLEFGVAQGVDMIFASFIRTAEQVREVRAALGEKGKDILIISKIENHQGVQNIDSIIEASNGIMVARGDLGVEIPAEKVCVAQMCIISKCNVVGKPVICATQMLESMTSNPRPTRAEVSDVANAVLNGADCVMLSGETAKGKYPNEVVQYMARICVEAQSATHDTVMFNSIKNLQKIPMCPEEAVCSSAVASAFEVQAKAMLVLSNTGRSARLISKYRPNCPIICVTTRLQTCRQLNVTRSVVSVFYDAA-KSGEDKDKEKRVKLGLDFAKKEKYASTGDVVVVVHADHSVKGYPNQTRLIYL 498
10 -130.0006DU6 Entity 1(prereleased)  ali follow..  50  41.SHLEHMCSLDIDSQTAVRLSGIICTIGPASVAPEMLEKMMATGMNIARLNFSHGSHEYHANTIKNIREAVDNYSPFPLAIALDTKGPEIRTGLIEGSGEVELKKGEQIQLTTDKDHLEKGSKDKIFVDYVNIVKVVKKGDRVFVDDGLISLVVDSI-SGDTLTCTVENGGLLGSRKGVNLPGVPVDLPAVSEKDKSDLQFGVEQGVDVIFASFIRNAAALKEIRTILGEKGKNIKIISKIENQQGMQNLDAIIAASDGIMVARGDLGIEIPAEKVFLAQKSMIARCNRAGKPVICATQMLESMIKKPRPTRAEISDVANAIIDGADCVMLSGETAKGEYPLECVLTMAKTCKEAEAALWHRNLFNDLVNTTPTPLDTASSIAIAASEAAAKSRAAAVIVITTSGRSAHLISKYRPRCPIIAVTRFAQTARQCHLYRGILPVIYEQQALEDWLKDVDARVQYGMDFGKERGFLKPGNPVVVVTGWKQGSGFTNTIRIVNV 546
11 -130.0003e0v_A mol:protein length:539 Pyruvate kinase  ali model follow..  47  30.SQLAHNLTLSIFDPVNYRAARIICTIGPSTQSVEALKGLIQSGMSVARMNFSHGSHEYHQTTINNVRQAAAEL-GVNIAIALDTKGPEIRTGQFVGG-DAVMERGATCYVTTDPAFADKGTKDKFYIDYQNLSKVVRPGNYIYIDDGILILQVQSHEDEQTLECTVTNSHTISDRRGVNLPGCDVDLPAVSAKDRVDLQFGVEQGVDMIFASFIRSAEQVGDVRKALGPKGRDIMIICKIENHQGVQNIDSIIEESDGIMVARGDLGVEIPAEKVVVAQKILISKCNVAGKPVICATQMLESMTYNPRPTRAEVSDVANAVFNGADCVMLSGETAKGKYPNEVVQYMARICLEAQSALNEYVFFNSIKKLQHIPMSADEAVCSSAVNSVYETKAKAMVVLSNTGRSARLVAKYRPNCPIVCVTTRLQTCRQLNITQGVESVFFDA-DKLGHDWGKEHRVAAGVEFAKSKGYVQTGDYCVVIHADHKVKGYANQTRILLV 526
12 -129.0001t5a_A mol:protein length:567 Pyruvate kinase, M2 isozyme  ali model follow..  50  55.TFLEHMCRLDIDSPPTARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFAYRPVAVALDTKGPEIRTGLIKGSAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQK-GADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQNLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPV 560
13 -127.0004krz_A mol:protein length:519 Pyruvate kinase  ali model follow..  46  16.SQLAHNVNLSIFEPISHRANRIVCTIGPSTQSVEALKGLIRSGMSVARMNFSHGSHEYHQTTINNLRAAATEL-GAHIGLALDTKGPEIRTGLFKDG-GIALAPGDTVLVTSDPAFEKIGTKEKFYIEYPRLSITVRPGGFIYIDDGVLSLKVLSKEDEYTLKCYVNNAHFLTDRKGCNLPGCEVDLPAVSEKDREDLKFGVEQGIDMVFASFIRTAEQVQEVREALGEKGKDILIISKIENHQGVQNIDGIIEASDGIMVARGDLGVEIPAEKVVVAQMILISKCNVAGKPVICATQMLESMTTNPRPTRAEVSDVANAVFNGADCVMLSGETAKGKYPNEVVQYMARICLEAQSATNQAVMFNSIKKMQKLPMSPEEAVCSSAVNSVYEVRAKALLVLSNSGRSARLASKYRPDCPIICATTRMRTCRQLTITRSVDAVFYDA-ERYGEDENKEKRVQLGVDCAKKKGYVVPGDLMVVVHADHKVKGYPNQTRIIYV 512
14 -123.0001e0t_A mol:protein length:470 PYRUVATE KINASE  ali model follow..  42  1.................MKKTKIVCTIGPKTESEEMLAKMLDAGMNVMRLNFSHGDYAEHGQRIQNLRNVMSKT-GKTAAILLDTKGPEIRTMKLEGGNDVSLKAGQTFTFTTDKSV--IGNSEMVAVTYEGFTTDLSVGNTVLVDDGLIGMEVTAI-EGNKVICKVLNNGDLGENKGVNLPGVSIALPALAEKDKQDLIFGCEQGVDFVAASFIRKRSDVIEIREHLKAHGENIHIISKIENQEGLNNFDEILEASDGIMVARGDLGVEIPVEEVIFAQKMMIEKCIRARKVVITATMMLDSMIKNPRPTDAEAGDVANAILDGTDAVMLSGESAKGKYPLEAVSIMATICERTDRVMNSRLEFNNDNR----KLRITEAVCRGAVETAEKLDAPLIVVATQGGKSARAVRKYFPDATILALTTNEKTAHQLVLSKGVVPQLVKE------ITSTDDFYRLGKELALQSGLAHKGDVVVMVSGALVPSGTTNTASVHVL 470
15 -122.0003t05_A mol:protein length:606 Pyruvate kinase  ali model follow..  42  1...MGSSSSGLVPRGSHMRKTKIVCTIGPASESEEMIEKLINAGMNVARLNFSHGSHEEHKGRIDTIRKVAKRL-DKIVAILLDTKGPEIRTHNMKDG-IIELERGNEVIVSMNEV---EGTPEKFSVTYENLINDVQVGSYILLDDGLIELQVKDIDAKKEVKCDILNSGELKNKKGVNLPGVRVSLPGITEKDAEDIRFGIKENVDFIAASFVRRPSDVLEIREILEEQKANISVFPKIENQEGIDNIEEILEVSDGLMVARGDMGVEIPPEKVPMVQKDLIRQCNKLGKPVITATQMLDSMQRNPRATRAEASDVANAIYDGTDAVMLSGETAAGLYPEEAVKTMRNIAVSAEAAQDYKKLLSDRTKLVET--SLVNAIGISVAHTALNLNVKAIVAATESGSTARTISKYRPHSDIIAVTPSEETARQCSIVWGVQPVVKKG------RKSTDALLNNAVATAVETGRVTNGDLIIITAGVPTGTGTTNMMKIHLV 487
16 -120.0005wrp_A mol:protein length:475 Pyruvate kinase  ali model follow..  35  5.................TRRGKIVCTLGPATQRDDLVRALVEAGMDVARMNFSHGDYDDHKVAYERVRVASDAT-GRAVGVLADLQGPKIRLGRFASG-ATHWAEGETVRITVGAC---EGSHDRVSTTYKRLAQDAVAGDRVLVDDGKVALVVDAV-EGDDVVCTVVEGGPVSDNKGISLPGMNVTAPALSEKDIEDLTFALNLGVDMVALSFVRSPADVELVHEVMDRIGRRVPVIAKLEKPEAIDNLEAIVLAFDAVMVARGDLGVELPLEEVPLVQKRAIQMARENAKPVIVATQMLDSMIENSRPTRAEASDVANAVLDGADALMLSGETSVGKYPLAAVRTMSRIICAVEENSTAAPPLTHI------PRTKRGVISYAARDIGERLDAKALVAFTQSGDTVRRLARLHTPLPLLAFTAWPEVRSQLAMTWGTETFIVPK------MQSTDGMIRQVDKSLLELARYKRGDLVVIVAGAPPGVGSTNLIHVHRI 470
17 -119.0003khd_A mol:protein length:520 Pyruvate kinase  ali model follow..  41  21AANITLRQILEPNNVNRSKKTHIVCTLGPACKSVETLVKLIDAGMDICRFNFSHGSHEDHKEMFNNVLKAQELRPNCLLGMLLDTKGPEIRTGFLKNK-EVHLKEGSKLKLVTDYEF--LGDETCIACSYKKLPQSVKPGNIILIADGSVSCKVLET-HEDHVITEVLNSAVIGERKNMNLPNVKVDLPIISEKDKNDLNFAIPMGCNFIAASFIQSADDVRLIRNLLGPRGRHIKIIPKIENIEGIIHFDKILAESDGIMIARGDLGMEISPEKVFLAQKLMISKCNLQGKPIITATQMLESMTKNPRPTRAEVTDVANAVLDGTDCVMLSGETAGGKFPVEAVTIMSKICLEAEACIDYKLLYQSLVNAIETPISVQEAVARSAVETAESIQASLIIALTETGYTARLIAKYKPSCTILALSASDSTVKCLNVHRGVTCIKVGS------FQGTDIVIRNAIEIAKQRNMAKVGDSVIAIHGIKEESGGTNLMKVVQI 513
18 -119.0003eoe_A mol:protein length:511 Pyruvate kinase  ali model follow..  41  13.IRMSQILEPRSEEDWTAHRTRIVCTMGPACWNVDTLVKMIDAGMNVCRLNFSHGDHETHARTVQNIQEAMKQRPEARLAILLDTKGPEIRTGFLKDHKPITLQQGATLKIVTDYNL--IGDETTIACSYGALPQSVKPGNTILIADGSLSVKVVEV-GSDYVITQAQNTATIGERKNMNLPNVKVQLPVIGEKDKHDLNFGIPMGCNFIAASFVQSADDVRYIRGLLGPRGRHIRIIPKIENVEGLVNFDEILAEADGIMIARGDLGMEIPPEKVFLAQKMMIAKCNVVGKPVITATQMLESMIKNPRPTRAEAADVANAVLDGTDCVMLSGETANGEFPVITVETMARICYEAETCVDYPALYRAMCLAVPPPISTQEAVARAAVETAECVNAAIILALTETGQTARLIAKYRPMQPILALSASESTIKHLQVIRGVTTMQVPS------FQGTDHVIRNAIVVAKERELVTEGESIVAVHGMKEEAGSSNLLKVLTV 504
19 -118.0004drs_A mol:protein length:526 Pyruvate kinase  ali model follow..  39  27.LGMDKICSPLADNDVTQRKTQIICTIGPSCNNVESLIGLIDKGMSVARLNFSHGDHESHFKTLQNIREAAKARPHSTVGIMLDTKGPEIRTGMLEGGKPIELKAGQTLKITTDYSM--LGNSECISCSYSLLPKSVQIGSTVLIADGSLSTQVLEI-GDDFIVCKVLNSVTIGERKNMNLPGCKVHLPIIGDKDRHDIDFALKYNLDFIALSFVQNGADVQLCRQIISENTQSIKIISKIENLEGVINFDSICSESDGIMVARGDLGMEIPPEKIFVAQKCMISKCNVAGKPVVTATQMLESMIKSNRPTRAEMTDVANAVLDGSDCVMLSGETANGAFPFDAVNVMSRVCAQAETCIDYPVLYHAIHSSVPKPVAVPEAIACSAVESAHDVNAKLIITITETGNTARLISKYRPSQTIIACTAKPEVARGLKIARGVKTYVLNS------IHHSEVVISNALALAKEESLIESGDFAIAVHGVKESPGSCNLMKIVRC 525
20 -118.0002e28_A mol:protein length:587 Pyruvate kinase  ali model follow..  42  2.................KRKTKIVSTIGPASESVDKLVQLMEAGMNVARLNFSHGDHEEHGRRIANIREAAKRT-GRTVAILLDTKGPEIRTHNMENG-AIELKEGSKLVISMSEV---LGTPEKISVTYPSLIDDVSVGAKILLDDGLISLEVNAVDQAGEIVTTVLNGGVLKNKKGVNVPGVKVNLPGITEKDRADILFGIRQGIDFIAASFVRRASDVLEIRELLEAHALHIQIIAKIENEEGVANIDEILEAADGLMVARGDLGVEIPAEEVPLIQKLLIKKSNMLGKPVITATQMLDSMQRNPRPTRAEASDVANAIFDGTDAVMLSGETAAGQYPVEAVKTMHQIALRTEQALEHRDILSQRTK--ESQTTITDAIGQSVAHTALNLDVAAIVTPTVSGKTPQMVAKYRPKAPIIAVTSNEAVSRRLALVWGVYTKEAPH------VNTTDEMLDVAVDAAVRSGLVKHGDLVVITAGVPVGTGSTNLMKVHVI 474
21 -118.0003ma8_A mol:protein length:534 Pyruvate kinase  ali model follow..  39  21.CTLGKATCLGMDKDVTQRKTQIICTIGPSCNNVESLIGLIDKGMSVARLNFSHGDHESHFKTLQNIREAAKARPHSTVGIMLDTKGPEIRTGMLEGGKPIELKAGQTLKITTDYSM--LGNSECISCSYSLLPKSVQIGSTVLIADGSLSTQVLEI-GDDFIVCKVLNSVTIGERKNMNLPGCKVHLPIIGDKDRHDIDFALKYNLDFIALSFVQNGADVQLCRQIISENTQSIKIISKIENLEGVINFDSICSESDGIMVARGDLGMEIPPEKIFVAQKCMISKCNVAGKPVVTATQMLESMIKSNRPTRAEMTDVANAVLDGSDCVMLSGETANGAFPFDAVNVMSRVCAQAETCIDYPVLYHAIHSSVPKPVAVPEAIACSAVESAHDVNAKLIITITETGNTARLISKYRPSQTIIACTAKPEVARGLKIARGVKTYVLNS------IHHSEVVISNALALAKEESLIESGDFAIAVHGVKESPGSCNLMKIVRC 527
22 -113.0003qtg_A mol:protein length:461 Pyruvate kinase  ali model follow..  28  1......MSAPRGDHAIARNLTKRVATLGPSTDVLRPDELIFLDLVDGVRINLAHASPNEVKFRIEAVRSYEKAK-NRPLAVIVDLKGPSIRVGSTSP---INVQEGEVVKFKLSD----KSDGTYIPVPNKAFFSAVEQNDVILMLDGRLRLKVTNT-GSDWIEAVAESSGVITGGKAIVVEGKDYDISTPAEEDVEALKAPIRDNIDYVAISLAKSCKDVDSVRSLLTELGFQSQVAVKIETKGAVNNLEELVQCSDYVVVARGDLGLHYGLDALPIVQRRIVHTSLKYGKPIAVATQLLDSMQSSPIPTRAEINDVFTTASMGVDSLWLTNETASGKYPLAAVSWLSRILMNVEYQIPQSPLLQ----------NSRDRFAKGLVELAQDLGA-NILVFSMSGTLARRIAKFRPRGVVYVGTPNVRVARSLSIVWALEPLYIPAENYE--------------EGLEKLISLKGTTPFVATYGIR---GGVHSVKVK.. 460
23 -9.8701sgj_A mol:protein length:284 citrate lyase, beta subunit  ali model follow..  16  31............................................................................................................................................DAVVID---LEDAVPGTAEAKAAARPVAHDAARDLIAAAPHLAVFVRVNALHSPYFEDDLSVLTPELSGVVVPKLEMGAEARQVAQMLQERSLPLPILAGLETGAGVWNAREIMEVPAWAYFGAEDYTTDLGGKEVLYARSQVALAARLTG---VAALDIVVTALNDPETFRADAEQGRALGYSGKLCI----------HPAQ-VALAHEYFGPTEADRARARALLDAAAAAAQRGHGAFSFEGQMVDEPMLAKARTLLSHEA................................................................................................. 284
24 -9.6204tv5_A mol:protein length:259 2-dehydro-3-deoxyglucarate aldolase  ali model follow..  14  70...........................................................................................................................................................................................IVRVTAVIDRDIIKVLDMGARGIIVPHVKDRETVEHILDAMEMANEHIMVIAMIEDVEGVMAIDDIAQVEDMIVEGAADLSQSLGIDQVTSHVQHIFEVVNAHGKHF--------ALPREDEDIAKWQAQGVQTFILGDDRGKIYRHLSA................................................................................................................................................................... 247
25 -9.5703qz6_A mol:protein length:261 HpcH/HpaI aldolase  ali model follow..  17  70...........................................................................................................................................................................................LVRIPQVDRAHVQRLLDIGAEGFMIPGVQSAETMRETAEWVQERNDEIFIMAQIEHVKAVEDIDSILAVQDAVIFGPRDLSNDLGIPKVYECYEKVYRAADRQGVVTAADAAKMGWAVERGAQMLLWSGDVA-ALQTYTAKGVKTIKELPGFNP............................................................................................................................................................... 261
26 -9.5403qll_A mol:protein length:316 Citrate lyase  ali model follow..  14  51..................................................................................................................................DRFAKAAENGADVAIIDLEDSVSQADKEQARQKAISYLSSRPATSLP------LALRINGLTRAGIEDIHALLECGPDYLVLPKTESAAHLQILDRLMMFAGSDTRLIGIIESVRGLNAVESIAAATPKLALIFGDIGAASTWEPLALARARLVSACAMNGIPAIDAPFF----VHDVSGLQSETLRASDFGFSAKAAI----------HPAQ-ISTINTLFTPTAAEIRHAR......................................................................................................................................... 273
27 -9.0502vws_A mol:protein length:267 YFAU, 2-KETO-3-DEOXY SUGAR ALDOLASE  ali model follow..  20  71..........................................................................................................................................................................................PVIRPVEGSKPLIKQVLDIGAQTLLIPMVDTAEQARQVENYMAQVNDSLCLLVQVESKTALDNLDEILDVEDGVFIGPADLSASLGYPEVQRIIETSIRRIRAAGKAA--------FLAVAPDMAQQCLAWGANFVAVGVDTMLYSDALD.................................................................................................................................................................... 248
FFAS is supported by the NIH grant R01-GM087218-01
1 4 8 3 1 6   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster
Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Dunbrack RL Jr, Dunker K, Godzik A. Protein structure prediction in biology and medicine. Pac Symp Biocomput. 2000;(12):93-4.